RTP Mobile Logo
Submitted by web@researchtop... on Fri, 06/28/2019 - 13:22
MPNUpdate117
 
Track 1: Pathophysiology, symptoms and common genetic mutations associated with Waldenström macroglobulinemia (WM)
Track 2: Somatic mutations in MYD88 (L265P) and CXCR4 and implications for prognosis and therapy
Track 3: Diagnostic criteria for WM
Track 4: Case (Dr Treon): A man in his late 60s with WM experiences an IgM flare and worsening peripheral neuropathy during first-line treatment with rituximab
Track 5: Indications for the initiation of therapy for patients with WM
Track 6: Management approach for patients with WM experiencing IgM flare after treatment with rituximab
Track 7: Activity of the BTK (Bruton tyrosine kinase) inhibitor ibrutinib alone or in combination with rituximab in patients with WM
Track 8: Perspective on the use of ibrutinib with or without rituximab as front-line therapy for WM
Track 9: Symptoms and management of hyperviscosity syndrome associated with WM
Track 10: Role of obinutuzumab in the management of WM
Track 11: Case (Dr Dimopoulos): A man in his early 50s with WM and a MYD88 L265P mutation attains a very good partial response to first-line therapy with bortezomib/dexamethasone/rituximab
Track 12: Selection of therapy for patients with WM in the first-line setting
Track 13: Efficacy and tolerability of proteasome inhibitors for WM
Track 14: Peripheral neuropathy associated with WM and implications for therapy
Track 15: Duration of ibrutinib therapy for WM and impact of treatment holidays
Track 16: Side effects associated with ibrutinib; monitoring and management of atrial fibrillation
Track 17: Case (Dr Treon): A woman in her mid-60s diagnosed with WM and a MYD88 L265P mutation experiences a dramatic response after receiving ibrutinib as first-line therapy
Track 18: Response and tolerability with ibrutinib in the front-line setting
Track 19: Case (Dr Dimopoulos): A woman in her early 80s with a history of hypertension and atrial fibrillation is diagnosed with WM with a MYD88 L265P mutation and receives ibrutinib and anticoagulation therapy
Track 20: Perspective on the use of ibrutinib for elderly patients and those with a history of atrial fibrillation
Track 21: Activity of the BTK inhibitor zanubrutinib in patients with WM
Track 22: Results of the Phase III iNNOVATE trial evaluating ibrutinib with rituximab versus rituximab alone for patients with previously untreated or relapsed/refractory WM
Track 23: Ongoing investigation of CXCR4 inhibitors and the Bcl-2 inhibitor venetoclax for WM
Track 24: Biologic rationale and role for venetoclax in WM
Track 25: Tumor lysis syndrome associated with venetoclax
Track 26: Novel agents and approaches under investigation for WM
Track 27: Therapeutic options for patients with WM after disease progression on ibrutinib
 
FACULTY
 
Meletios A Dimopoulos, MD
Department of Medical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Athens, Greece
 
Steven P Treon, MD, PhD
Professor, Harvard Medical School
Lead Physician
Dana-Farber Cancer Institute
Director
Bing Center for Waldenström’s Macroglobulinemia
Boston, Massachusetts
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida